Blockade of Chronic Type I Interferon Signaling to Control Persistent LCMV Infection
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Type I interferons (IFN-I) are critical for antiviral immunity; however, chronic IFN-I signaling is associated with hyperimmune activation and disease progression in persistent infections. We demonstrated in mice that blockade of IFN-I signaling diminished chronic immune activation and immune suppression, restored lymphoid tissue architecture, and increased immune parameters associated with control of virus replication, ultimately facilitating clearance of the persistent infection. The accelerated control of persistent infection induced by blocking IFN-I signaling required CD4 T cells and was associated with enhanced IFN-γ production. Thus, we demonstrated that interfering with chronic IFN-I signaling during persistent infection redirects the immune environment to enable control of infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, during viral infections, chronic type I and II IFN signaling can lead to immune suppression and a failure to clear viral infection.51-53”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [52]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
Functional Role of Type I and Type II Interferons in Antiviral Defense
Müller, U., Steinhoff, U., Reis, L. F. L., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., & Aguet, M. (1994) · Science · doi:10.1126/science.8009221 · Cited by 2,453
Type I Interferon Inhibits Interleukin-1 Production and Inflammasome Activation
Guarda, G., Braun, M., Staehli, F., Tardivel, A., Mattmann, C., Förster, I., Farlik, M., Decker, T., Du Pasquier, R. A., Romero, P., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.02.006 · Cited by 933
Interleukin-10 determines viral clearance or persistence in vivo
Brooks, D. G., Trifilo, M. J., Edelmann, K. H., Teyton, L., McGavern, D. B., & Oldstone, M. B. A. (2006) · Nature Medicine · doi:10.1038/nm1492 · Cited by 923
Self-citationInterferon signaling and treatment outcome in chronic hepatitis C
Sarasin-Filipowicz, M., Oakeley, E. J., Duong, F. H. T., Christen, V., Terracciano, L., Filipowicz, W., & Heim, M. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707882105 · Cited by 642
Resolution of a chronic viral infection after interleukin-10 receptor blockade
Ejrnaes, M., Filippi, C. M., Martinic, M. M., Ling, E. M., Togher, L. M., Crotty, S., & von Herrath, M. G. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061462 · Cited by 548
Jacquelin, B., Mayau, V., Targat, B., Liovat, A.-S., Kunkel, D., Petitjean, G., Dillies, M.-A., Roques, P., Butor, C., Silvestri, G., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci40093 · Cited by 481
Constitutive Type I Interferon Modulates Homeostatic Balance through Tonic Signaling
Gough, D. J., Messina, N. L., Clarke, C. J. P., Johnstone, R. W., & Levy, D. E. (2012) · Immunity · doi:10.1016/j.immuni.2012.01.011 · Cited by 470
Pathogenic Mechanisms of HIV Disease
Moir, S., Chun, T.-W., & Fauci, A. S. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130254 · Cited by 463
Research works printed but not linked: 2
- Brockman MA Blood 2009 114 346 19365081 PMC2714209 · DOI · Paper page
- 10.1089/jir.2012.0037 · DOI
Cited by
Items 101–200 of 713
Type I/II Interferon Balance in the Regulation of Brain Physiology and Pathology
Deczkowska, A., Baruch, K., & Schwartz, M. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.006 · Cited by 143
Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes
Qi, Y., Liu, B., Sun, Q., Xiong, X., & Chen, Q. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.578877 · Cited by 146
Interferons and the immunogenic effects of cancer therapy
Minn, A. J. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.09.007 · Cited by 130
“Accordingly, this subset of ISGs overlaps with the ISGs elevated during chronic viral infection models in mice and in patients with chronic viral infection [39,40].”
BackgroundYu, X., Cai, B., Wang, M., Tan, P., Ding, X., Wu, J., Li, J., Li, Q., Liu, P., Xing, C., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.001 · Cited by 126
“Previous studies showed that type I IFN signaling inhibits type II IFN (IFN-g) or adaptive immune responses upon malaria and viral infection (Haque et al., 2011; Palomo et al., 2013; Teijaro et al., 2013; Teles et al., 2013; Wilson et al., 2013).”
ResultTargeting of type I interferon in systemic autoimmune diseases
Crow, M. K., Olferiev, M., & Kirou, K. A. (2015) · Translational Research · doi:10.1016/j.trsl.2014.10.005 · Cited by 122
Alveolar macrophages and type I IFN in airway homeostasis and immunity
Divangahi, M., King, I. L., & Pernet, E. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.03.005 · Cited by 142
NK Cells and Their Ability to Modulate T Cells during Virus Infections
Cook, K. D., Waggoner, S. N., & Whitmire, J. K. (2014) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2014010604 · Cited by 133
Nakayamada, S., Poholek, A. C., Lu, K. T., Takahashi, H., Kato, M., Iwata, S., Hirahara, K., Cannons, J. L., Schwartzberg, P. L., Vahedi, G., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1300675 · Cited by 120
Type III IFNs: Beyond antiviral protection
Kotenko, S. V., Rivera, A., Parker, D., & Durbin, J. E. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101303 · Cited by 132
Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis
Ebert, G., Allison, C. C., Preston, S., Cooney, J. P., Toe, J. G., Stutz, M. D., Ojaimi, S., Baschuk, N., Nachbur, U., Torresi, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502400112 · Cited by 122
Gangaplara, A., Martens, C., Dahlstrom, E., Metidji, A., Gokhale, A. S., Glass, D. D., Lopez-Ocasio, M., Baur, R., Kanakabandi, K., Porcella, S. F., et al. (2018) · PLOS Pathogens · doi:10.1371/journal.ppat.1006985 · Cited by 115
Advances in understanding the role of type I interferons in systemic lupus erythematosus
Crow, M. K. (2014) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000087 · Cited by 122
Viral oncogenesis in cancer: from mechanisms to therapeutics
Xiao, Q., Liu, Y., Li, T., Wang, C., He, S., Zhai, L., Yang, Z., Zhang, X., Wu, Y., & Liu, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02197-9 · Cited by 131
Macrophage Polarization in Virus-Host Interactions
Laura C Miller, Y. S. (2015) · Journal of Clinical and Cellular Immunology · doi:10.4172/2155-9899.1000311 · Cited by 110
“However, two recent studies have indicated that blockade of chronic type I IFN signaling facilitates restoration of effective immune status and ultimately leads to clearance of the persistent infection by lymphocytic choriomeningitis virus (LCMV) [121,122].”
BackgroundLi, G., Cheng, M., Nunoya, J.-I., Cheng, L., Guo, H., Yu, H., Liu, Y.-J., Su, L., & Zhang, L. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004291 · Cited by 115
“Two recent reports showed that blocking IFN-I signaling during LCMV persistent infection could improve antiviral T cell response and accelerate clearance of chronic LCMV infection via an IL-10related mechanism [66,67].”
Out-of-Sequence Signal 3 Paralyzes Primary CD4+ T-Cell-Dependent Immunity
Sckisel, G. D., Bouchlaka, M. N., Monjazeb, A. M., Crittenden, M., Curti, B. D., Wilkins, D. E. C., Alderson, K. A., Sungur, C. M., Ames, E., Mirsoian, A., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.06.023 · Cited by 106
“Other studies suggest that elevated cytokine concentrations might play a role in propagating the exhaustion that occurs during chronic infections (Teijaro et al., 2013;Wilson et al., 2013).”
BackgroundMelo, M. B., Nguyen, Q., Cordeiro, C. A., Hassan, M. A., Yang, N., McKell, R., Rosowski, E. E., Julien, L., Butty, V. L., Dardé, M., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003779 · Cited by 122
“Importantly, type I interferons can affect infection persistence [65,66], which depends on both timing and magnitude”
Role of CD4+ T Cells in the Control of Viral Infections: Recent Advances and Open Questions
Kervevan, J., & Chakrabarti, L. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020523 · Cited by 126
Dendritic cell dysregulation during HIV ‐1 infection
Miller, E., & Bhardwaj, N. (2013) · Immunological Reviews · doi:10.1111/imr.12082 · Cited by 127
“Recent work with LCMV infection in mice supports these observations and implicates a potential therapeutic role for blockade of type I interferon signaling in chronic infection (188, 189).”
BackgroundType I IFN signaling in CD8– DCs impairs Th1-dependent malaria immunity
Haque, A., Best, S. E., Montes de Oca, M., James, K. R., Ammerdorffer, A., Edwards, C. L., de Labastida Rivera, F., Amante, F. H., Bunn, P. T., Sheel, M., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70698 · Cited by 113
“Type I IFNs are crucial for protection against viruses but can facilitate survival of many pathogens, such as Listeria (1, 2), Mycobac-teria (3–7), Staphylococci (8), and Lymphocytic choriomen ingitis virus (9, 10), as well as protozoan parasites, such as Leishmania (11) and Plasmodium (12).”
Interferon-driven deletion of antiviral B cells at the onset of chronic infection
Fallet, B., Narr, K., Ertuna, Y. I., Remy, M. M., Sommerstein, R., Cornille, K., Kreutzfeldt, M., Pagé, N., Zimmer, G., Geier, F., et al. (2016) · Science Immunology · doi:10.1126/sciimmunol.aah6817 · Cited by 119
“The essential antiviral role of IFN-I may preclude the success of αIFNARbased immunomodulatory therapy ((15, 16, 29), Fig.”
InfluentialType I Interferons Modulate CD8 + T Cell Immunity to mRNA Vaccines
Beuckelaer, A. D., Grooten, J., & Koker, S. D. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.01.006 · Cited by 122
Multifaceted Activities of Type I Interferon Are Revealed by a Receptor Antagonist
Levin, D., Schneider, W. M., Hoffmann, H.-H., Yarden, G., Busetto, A. G., Manor, O., Sharma, N., Rice, C. M., & Schreiber, G. (2014) · Science Signaling · doi:10.1126/scisignal.2004998 · Cited by 113
“(52) addressed this question and found that IFNs can also suppress the immune system in ways that promote viral persistence.”
BackgroundType I Interferons as Regulators of Human Antigen Presenting Cell Functions
Gessani, S., Conti, L., Cornò, M. D., & Belardelli, F. (2014) · Toxins · doi:10.3390/toxins6061696 · Cited by 119
“Specifically, a reduced antiviral response has been observed in mice persistently infected with lymphocytic choriomeningitis virus (LCMV), and this unresponsiveness has been associated with the IFN-mediated induction of IL-10 and programmed cell death 1 ligand 1 (PD-L1) expression in DCs [76,77].”
BackgroundThe crucial regulatory role of type I interferon in inflammatory diseases
Ji, L., Li, T., Chen, H., Yang, Y., Lu, E., Liu, J., Qiao, W., & Chen, H. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01188-z · Cited by 121
“IFN-Is have also been observed to dampen T cell responses by promoting the expression of immunosuppressive genes such as IL-10 and programmed cell death 1 ligand 1 (PDL1) to facilitate persistent virus infection [232].”
BackgroundOsokine, I., Snell, L. M., Cunningham, C. R., Yamada, D. H., Wilson, E. B., Elsaesser, H. J., de la Torre, J. C., & Brooks, D. G. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1401662111 · Cited by 113
“To evaluate the role of IFN-I in modulating Th1 differentiation during persistent infection, we treated animals with an antibody that blocks IFN-I receptor (IFNR) signaling in vivo (21, 22).”
BackgroundSelf-citationSARS-CoV and IFN: Too Little, Too Late
Kindler, E., & Thiel, V. (2016) · Cell Host & Microbe · doi:10.1016/j.chom.2016.01.012 · Cited by 101
“…potential, accompanied with chronic immune activation during persistent lymphocytic choriomeningitis virus infection (Teijaro et al., 2013; Wilson et al., 2013), or pathogenic potential, manifested by increased lung damage during acute influenza virus infection (Davidson et al., 2014).”
BackgroundDual Nature of Type I Interferons in SARS-CoV-2-Induced Inflammation
King, C., & Sprent, J. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.02.003 · Cited by 114
“IFN-I therapy delivered after infection might exacerbate inflammation by direct stimulatory effects on both innate immune cell subsets and T cells, but with time, can also act to suppress the adaptive immune response by inducing T cell exhaustion [70,71].”
de, M. M., Kumar, R., Rivera, F. D. L., Amante, F. H., Sheel, M., Faleiro, R. J., Bunn, P. T., Best, S. E., Beattie, L., Ng, S. S., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.09.015 · Cited by 111
“…pathogen survival by suppressing immunity during infections, such as those caused by lymphocytic choriomeningitis virus (Teijaro et al., 2013; Wilson et al., 2013), influenza (Arimori et al., 2013), Mycobacteria (Antonelli et al., 2010; Berry et al., 2010; Desvignes et al., 2012; Stanley et…”
BackgroundVukmanovic-Stejic, M., Chambers, E. S., Suárez-Fariñas, M., Sandhu, D., Fuentes-Duculan, J., Patel, N., Agius, E., Lacy, K. E., Turner, C. T., Larbi, A., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.10.032 · Cited by 103
“Type I interferon has been shown to interfere with antigenspecific T-cell responses, and excessive levels of these mediators impair the clearance of both viral and mycobacterial infections in mice in vivo.(36,37) In the present studywe also found a strong type I interferon signature in the skin of old subjects after s…”
Ng, C. T., Snell, L. M., Brooks, D. G., & Oldstone, M. B. A. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.05.014 · Cited by 100
“, 2013), Cl-13 infection induced significantly higher IFN-I levels and IFN-stimulated gene expression than acute ARM infection (Teijaro et al., 2013; Wilson et al., 2013), consistent with the association between high levels of IFN-I signaling and persistence.”
BackgroundResultInfluentialSelf-citationMalireddi, R. K. S., & Kanneganti, T. (2013) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2013.00077 · Cited by 113
“It will be essential to study the contribution of type I IFN in pyroptosis induction during B. anthracis infection and investigate whether type I IFN can promote apoptosis of neutrophils and initiate other possible detrimental effects.”
BackgroundBystander Chronic Infection Negatively Impacts Development of CD8+ T Cell Memory
Stelekati, E., Shin, H., Doering, T. A., Dolfi, D. V., Ziegler, C. G., Beiting, D. P., Dawson, L., Liboon, J., Wolski, D., Ali, M.-A. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.04.010 · Cited by 97
“Moreover, blockade of IFNAR during chronic viral infection has recently been found to paradoxically benefit antiviral adaptive immune responses (Teijaro et al., 2013; Wilson et al., 2013).”
BackgroundLong-Term Persistence of Exhausted CD8 T Cells in Chronic Infection Is Regulated by MicroRNA-155
Stelekati, E., Chen, Z., Manne, S., Kurachi, M., Ali, M.-A., Lewy, K., Cai, Z., Nzingha, K., McLane, L. M., Hope, J. L., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.038 · Cited by 96
“Although inflammatory cytokines are essential for optimal T cell priming, persistent inflammation, and particularly type I IFN signaling during chronic infection, are detrimental for T cell differentiation (Stelekati et al., 2014; Teijaro et al., 2013; Wilson et al., 2013).”
Type I Interferon: Understanding Its Role in HIV Pathogenesis and Therapy
Bosinger, S. E., & Utay, N. S. (2015) · Current HIV/AIDS Reports · doi:10.1007/s11904-014-0244-6 · Cited by 100
Chyuan, I., Tzeng, H., & Chen, J.-Y. (2019) · Cells · doi:10.3390/cells8090963 · Cited by 107
“When the type I IFN signaling is blocked with anti-IFNAR antibodies, the immunotolerant state is reversed, DCs are further stimulated, and virus-specific CD4+ T cell immunity is enhanced, which consequently improves infection control [56,57].”
BackgroundCellular and molecular mechanisms of CD8(+) T cell differentiation, dysfunction and exhaustion
Verdon, D. J., Mulazzani, M., & Jenkins, M. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197357 · Cited by 98
“Type I interferons play an essential role in primary T cell activation, and in viral control; however, there is evidence to suggest that prolonged exposure to type I interferon signalling exacerbates T cell exhaustion [78], and that blocking IFNα/β during LCMV Clone 13 infection reversed T cell exhaustion [156].”
BackgroundJoosten, S. A., Fletcher, H. A., & Ottenhoff, T. H. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073230 · Cited by 109
“Interestingly in virus infection models the IFNa/b response mediated enhanced antiviral activity during acute infection but exerted strong immunomodulatory effects during chronic infection [51].”
BackgroundSnell, L. M., Osokine, I., Yamada, D. H., la Fuente, J. R. O. D., Elsaesser, H. J., & Brooks, D. G. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.065 · Cited by 103
“IFN-I signaling upregulates PD-L1 expression by DCs (activation-inducible PD-L1) but does not control the basal level of PDL1 expression on DCs in the absence of inflammatory signals (Wilson et al., 2013).”
BackgroundSelf-citationFraietta, J. A., Mueller, Y. M., Yang, G., Boesteanu, A. C., Gracias, D. T., Do, D. H., Hope, J. L., Kathuria, N., McGettigan, S. E., Lewis, M. G., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003658 · Cited by 97
“Our interpretations of these correlations are strongly supported by two very recent studies showing that persistent Type I IFN production in chronic (Clone 13) lymphocytic choriomeningitis virus (LCMV) infection is causatively associated with the loss of viral control and this effect is CD4+ T cell-dependent [67,68].”
ResultModulation of immune responses in lentiviral vector-mediated gene transfer
Annoni, A., Gregori, S., Naldini, L., & Cantore, A. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.04.012 · Cited by 99
Epigenetic Manipulation Restores Functions of Defective CD8+ T Cells From Chronic Viral Infection
Zhang, F., Zhou, X., DiSpirito, J. R., Wang, C., Wang, Y., & Shen, H. (2014) · Molecular Therapy · doi:10.1038/mt.2014.91 · Cited by 94
Wu, J., Tian, L., Yu, X. H., Pattaradilokrat, S., Li, J., Wang, M., Yu, W., Qi, Y., Zeituni, A. E., Nair, S. C., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1316467111 · Cited by 97
“Recent data from viral infection suggested that chronic high levels of IFN-I could lead to immunosuppression and prolonged infection (48, 49).”
BackgroundCheng, L., Yu, H., Li, G., Li, F., Ma, J., Li, J., Chi, L., Zhang, L., & Su, L. (2017) · JCI Insight · doi:10.1172/jci.insight.94366 · Cited by 100
“During chronic LCMV infection in mice, blocking IFN-I signaling with an anti-IFNAR1 mAb can enhance antiviral immune responses and prevent or accelerate clearance of persistent LCMV infection in mice (16, 17).”
BackgroundCellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus
Ebert, G., Preston, S., Allison, C. C., Cooney, J. P., Toe, J. G., Stutz, M. D., Ojaimi, S., Scott, H. W., Baschuk, N., Nachbur, U., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502390112 · Cited by 102
“Clear immune effects were observed in LCMV-infected mice, consistent with published reports (14, 15).”
ResultAging and Interferons: Impacts on Inflammation and Viral Disease Outcomes
Feng, E., Balint, E., Poznanski, S. M., Ashkar, A. A., & Loeb, M. (2021) · Cells · doi:10.3390/cells10030708 · Cited by 82
The role of type I interferons in intestinal infection, homeostasis, and inflammation
Cho, H., & Kelsall, B. L. (2014) · Immunological Reviews · doi:10.1111/imr.12195 · Cited by 102
“Deleterious immunosuppressive effects of IFN-I signaling during persistent lymphocytic choriomeningitis virus (LCMV) infection have been recently described (179, 180).”
BackgroundXin, G., Zander, R., Schauder, D., Yao, C., Weinstein, J. S., Drobyski, W. R., Tarakanova, V. L., Craft, J. E., & Cui, W. (2018) · Nature Communications · doi:10.1038/s41467-018-07492-4 · Cited by 98
Key, F. M., Lewis, B. P., Dennis, M. Y., Huerta‐Sánchez, E., Tang, W., Prokunina‐Olsson, L., Nielsen, R., & Andrés, A. M. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004681 · Cited by 100
“It is perhaps surprising that suppression of an antiviral protein results in improved viral clearance, although it has for example been shown that during chronic infection blockage of persistent signaling of IFN I (a different type of interferon) can improve viral clearance [37,38].”
Interferons and HIV Infection: The Good, the Bad, and the Ugly
Utay, N. S., & Douek, D. C. (2016) · Pathogens and Immunity · doi:10.20411/pai.v1i1.125 · Cited by 86
“In the LCMV mouse model, blockade of type I IFN signaling improved antigen-specific CD4+ T-cell responses [40, 41], so type I IFNs not only suppress CD4+ T-cell recovery but also functionality.”
Im, S. J., Obeng, R. C., Nasti, T. H., McManus, D. T., Kamphorst, A. O., Gunisetty, S., Prokhnevska, N., Carlisle, J. W., Yu, K., Sica, G., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221985120 · Cited by 97
“It is well documented that type I IFNs (IFNIs) are induced at high levels during viral infections, while the production of IFN- Is is much lower in a tumor setting (32, 33).”
BackgroundMoseman, E. A., Wu, T., de la Torre, J. C., Schwartzberg, P. L., & McGavern, D. B. (2016) · Science Immunology · doi:10.1126/sciimmunol.aah3565 · Cited by 91
“An acute infection was generated by infecting mice with low-dose (4 × 104 PFU) LCMV CL13 M1. r3LCMV-iCre infections were achieved by intravenous injection of 3 × 104 PFU.”
BackgroundInfluentialReduction of HBV replication prolongs the early immunological response to IFNα therapy
Tan, A. T., Hoang, L. T., Chin, D. J., Rasmussen, E., Lopatin, U. A., Hart, S., Bitter, H., Chu, T., Gruenbaum, L. M., Ravindran, P., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.08.020 · Cited by 92
“Interestingly, work performed in a chronic murine LCMV infection model illustrates a dichotomous effect of IFNa [23,24].”
BackgroundInterferons as Essential Modulators of Atherosclerosis
Boshuizen, M. C. S., & de Winther, M. P. J. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305464 · Cited by 97
Iwata, S., Mikami, Y., Sun, H.-W., Brooks, S. R., Jankovic, D., Hirahara, K., Onodera, A., Shih, H.-Y., Kawabe, T., Jiang, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.05.005 · Cited by 90
“As a control, we also analyzed T cells from wild-type and Tbx21 / mice infected with lymphocytic choriomeningitis virus (LCMV), a viral infection known to induce a dynamic type I IFN response (Teijaro et al., 2013; Wilson et al., 2013; Zhou et al., 2010).”
Plasmacytoid dendritic cells promote HIV-1–induced group 3 innate lymphoid cell depletion
Zhang, Z., Cheng, L., Zhao, J., Li, G., Zhang, L., Chen, W., Nie, W., Reszka-Blanco, N., Wang, F., & Su, L. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82124 · Cited by 91
Cellular and molecular waypoints along the path of T cell exhaustion
Lan, X., Zebley, C. C., & Youngblood, B. (2023) · Science Immunology · doi:10.1126/sciimmunol.adg3868 · Cited by 95
Tomasello, E., Pollet, É., Manh, T. V., Uzé, G., & Dalod, M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00526 · Cited by 94
“Acute versus chronic exposure to IFN-I can lead to strikingly opposite effects on a given cell type (13, 14, 231).”
BackgroundBohne, F., Londoño, M., Benítez, C., Miquel, R., Martínez‐Llordella, M., Russo, C., Ortíz, C., Bonaccorsi‐Riani, E., Brander, C., Bauer, T., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008793 · Cited by 91
“Although a causal link between high intrahepatic ISG expression and HCV-induced immunoregulation has not been established, the connection is supported by data derived from the murine lymphocytic choriomeningitis virus infectionmodel (33, 34), in which chronic IFN-I signaling directly induces CD8 T cell immune”
HIV-1 intron-containing RNA expression induces innate immune activation and T cell dysfunction
Akiyama, H., Miller, C. M., Ettinger, C. R., Belkina, A. C., Snyder-Cappione, J. E., & Gummuluru, S. (2018) · Nature Communications · doi:10.1038/s41467-018-05899-7 · Cited by 96
CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition
Andreu-Saumell, I., Rodríguez-García, A., Mühlgrabner, V., Giménez-Alejandre, M., Marzal, B., Castellsagué, J., Brasó‐Maristany, F., Calderón, H., Angelats, L., Colell, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47799-z · Cited by 94
“Although IRF7 induction can potentiate CAR-T cell activation and induce antitumor activity 47 , in certain contexts, type I IFN signaling can also orchestrate T cell immunosuppression 48,49 andinduceapoptosisonCAR-Tcells 50 .”
Metidji, A., Rieder, S. A., Glass, D. D., Cremer, I., Punkosdy, G. A., & Shevach, E. M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500036 · Cited by 87
“Lastly, two recent studies have demonstrated that inhibition of IFNAR signaling either genetically or by Ab blockade in chronic infection with LCMV led to a substantial reduction in virus titers and enhanced antiviral CD4 T cell responses (47, 48).”
BackgroundChen, P.-M., Katsuyama, E., Satyam, A., Li, H., Rubio, J., Jung, S., Andrzejewski, S., Becherer, J. D., Tsokos, M., Abdi, R., et al. (2022) · Science Advances · doi:10.1126/sciadv.abo4271 · Cited by 91
“In a model of chronic LCMV in fection, type 1 IFN signaling regulates immunosuppressive signals from dendritic cells, and blocking its signaling pathway improves viral clearance by promoting IFN –expressing CD4 + T cells ( 36 ).”
Clonal lineage tracing reveals mechanisms skewing CD8+ T cell fate decisions in chronic infection
Kasmani, M. Y., Zander, R., Chung, H. K., Chen, Y., Khatun, A., Damo, M., Topchyan, P., Johnson, K. E., Levashova, D., Burns, R., et al. (2023) · Journal of Experimental Medicine · doi:10.1084/jem.20220679 · Cited by 87
“, 2013), we reasoned that IRF7may play a more prominent role in the setting of persistent infection, given that type I IFN production is augmented during chronic viral infection, and ISGs remain elevated for several weeks after LCMV Cl13 infection (Teijaro et al., 2013; Wilson et al., 2013).”
BackgroundHemorrhagic Fever-Causing Arenaviruses: Lethal Pathogens and Potent Immune Suppressors
Brisse, M. E., & Ly, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00372 · Cited by 87
“Mice infected with the OW LCMV, which is capable of maintaining persistent infection with low levels of IFN1 signaling (225, 226), display”
BackgroundThe Role of Type I IFNs in Influenza: Antiviral Superheroes or Immunopathogenic Villains?
Wu, W., & Metcalf, J. P. (2020) · Journal of Innate Immunity · doi:10.1159/000508379 · Cited by 87
Tumor-necrosis factor impairs CD4+ T cell–mediated immunological control in chronic viral infection
Beyer, M., Abdullah, Z., Chemnitz, J. M., Maisel, D., Sander, J., Lehmann, C., Thabet, Y., Shinde, P. V., Schmidleithner, L., Köhne, M., et al. (2016) · Nature Immunology · doi:10.1038/ni.3399 · Cited by 86
AXL receptor tyrosine kinase is required for T cell priming and antiviral immunity
Schmid, E. T., Pang, I. K., Carrera Silva, E. A., Bosurgi, L., Miner, J. J., Diamond, M. S., Iwasaki, A., & Rothlin, C. V. (2016) · eLife · doi:10.7554/elife.12414 · Cited by 81
“For example, sustained production of type I IFNs during chronic lymphocytic choriomeningitis (LCMV) infection inhibited the generation of virus-specific T cells and prevented viral clearance (Teijaro et al., 2013; Wilson et al., 2013).”
BackgroundXu, Y., Yuen, P.-W., & Lam, J. K. W. (2014) · Pharmaceutics · doi:10.3390/pharmaceutics6030378 · Cited by 97
“It has been reported that prolonged expression of antigen may lead to the switch of type-1 IFN from an antiviral cytokine to an immunosuppressive cytokine [26], or may deplete the pool of memory T cells [27].”
BackgroundThe Dual Role of Exosomes in Hepatitis A and C Virus Transmission and Viral Immune Activation
Longatti, A. (2015) · Viruses · doi:10.3390/v7122967 · Cited by 86
“Although type I interferons are generally considered to be a major first line of host defense after viral infection recent studies suggest that sustained interferon production may in some way contribute to viral persistence [62–64].”
BackgroundNewson, J., Motwani, M. P., Kendall, A. C., Nicolaou, A., Muccioli, G. G., Alhouayek, M., Bennett, M., Van De Merwe, R., James, S., De Maeyer, R. P. H., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.08.098 · Cited by 77
“, 1997; Segal, 1996) or failure to engage adaptive immunity (Teijaro et al., 2013; Wilson et al., 2013) can also lead to chronic inflammation and autoimmunity.”
BackgroundThe Biology of Monocytes and Dendritic Cells: Contribution to HIV Pathogenesis
Wacleche, V. S., Tremblay, C. L., Routy, J., & Ancuța, P. (2018) · Viruses · doi:10.3390/v10020065 · Cited by 94
“In addition, CCR2low/neg classical monocytes suppressed CD8+ T-cells proliferation and IFN-γ release, indicating that these monocytes may postpone the development of the antiviral responses.”
BackgroundInfluentialLindquist, M. E., Zeng, K. X., Altamura, L. A., Daye, S. P., Delp, K. L., Blancett, C. D., Coffin, K. M., Koehler, J. W., Coyne, S. R., Shoemaker, C. J., et al. (2018) · Journal of Virology · doi:10.1128/jvi.01083-18 · Cited by 81
“In addition to their usefulness in severe-disease models, antibody blockade of IFN-I signaling was shown to increase viral clearance and control of a persistent lymphocytic choriomeningitis virus infection by altering the immune response (54, 55).”
BackgroundGaly, A. S. D., Menegatti, S., Fuentealba, J. R., Perrin, L., Lucibello, F., Helft, J., Darbois, A., Saitakis, M., Tosello, J., Rookhuizen, D. C., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abe8219 · Cited by 84
“10 of 15 during persistent infection enhanced CD4+ T cell–dependent virus clearance (59, 60).”
BackgroundHumanized Mouse Models for Human Immunodeficiency Virus Infection
Marsden, M. D., & Zack, J. A. (2017) · Annual Review of Virology · doi:10.1146/annurev-virology-101416-041703 · Cited by 82
“However, continuous type I IFN signaling in chronic viral infections can also contribute to persistent immune activation and can have deleterious effects on antiviral responses (51, 55).”
BackgroundNuclear RNF2 inhibits interferon function by promoting K33-linked STAT1 disassociation from DNA
Liu, S., Jiang, M., Wang, W., Liu, W., Song, X., Ma, Z., Zhang, S., Liu, L., Liu, Y., & Cao, X. (2017) · Nature Immunology · doi:10.1038/s41590-017-0003-0 · Cited by 81
Interfering with immunity: detrimental role of type I IFNs during infection
Stifter, S. A., & Feng, C. G. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402794 · Cited by 78
“Two recent studies demonstrated that, during chronic infection, the significantly elevated levels of PD-L1 and IL-10, as well as viral loads, are significantly reduced in Ifnar1 mice or WT animals treated therapeutically with a blocking Ab to the receptor (176, 177).”
BackgroundThe transcriptional profile of coronary arteritis in Kawasaki disease
Rowley, A. H., Wylie, K. M., Kim, K. A., Pink, A. J., Yang, A., Reindel, R., Baker, S. C., Shulman, S. T., Orenstein, J. M., Lingen, M. W., et al. (2015) · BMC Genomics · doi:10.1186/s12864-015-2323-5 · Cited by 81
“Chronic type I interferon responses can be involved in the pathogenesis of persistent viral infections and autoimmune diseases [42, 43], and therapies to ameliorate this response are under study [44].”
BackgroundZander, R. A., Guthmiller, J. J., Graham, A. C., Pope, R. L., Burke, B. E., Carr, D. J. J., & Butler, N. S. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005945 · Cited by 76
Cunningham, C. R., Champhekar, A. S., Tullius, M. V., Dillon, B. J., Zhen, A., la Fuente, J. R. O. D., Herskovitz, J., Elsaesser, H. J., Snell, L. M., Wilson, E. B., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005356 · Cited by 87
“Simultaneous with its critical antiviral role, IFN-I signaling led to a surprising amount of the immune dysfunctions associated with viral persistence including expression of IL-10 and PDL1 [10, 11].”
BackgroundInfluentialSelf-citationThe microRNA miR-31 inhibits CD8+ T cell function in chronic viral infection
Moffett, H. F., Cartwright, A. N. R., Kim, H.-J., Godec, J., Pyrdol, J., Äijö, T., Martinez, G. J., Rao, A., Lu, J., Golub, T. R., et al. (2017) · Nature Immunology · doi:10.1038/ni.3755 · Cited by 67
Therapeutic Depletion of Natural Killer Cells Controls Persistent Infection
Waggoner, S. N., Daniels, K. A., & Welsh, R. M. (2013) · Journal of Virology · doi:10.1128/jvi.03002-13 · Cited by 73
“This parallels recently published studies showing that early blockade of type 1 IFN activity enhanced viral loads but blockade of IFN activity later on, during persistence, reduced viral loads (16, 17).”
BackgroundResultMetabolic regulation by PD-1 signaling promotes long-lived quiescent CD8 T cell memory in mice
Kalia, V., Yuzefpolskiy, Y., Vegaraju, A., Xiao, H., Baumann, F. M., Jatav, S., Church, C. D., Prlic, M., Jha, A., Nghiem, P., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aba6006 · Cited by 76
“In agreement with this, type I IFNs, which are potent inducers of PDL1, have been found to exhibit elevated expression during chronic compared to acute LCMV infection, and blockade of IFN-I signaling leads to reduction of PD-L1 and control of persistent LCMV infection (83, 84).”
BackgroundWaffarn, E., Hastey, C. J., Dixit, N., Choi, Y. S., Cherry, S. R., Kalinke, U., Simon, S. I., & Baumgarth, N. (2015) · Nature Communications · doi:10.1038/ncomms9991 · Cited by 79
IL-27 promotes the expansion of self-renewing CD8+ T cells in persistent viral infection
Huang, Z., Žák, J., Pratumchai, I., Shaabani, N., Vartabedian, V. F., Nguyen, N., Wu, T., Xiao, C., & Teijaro, J. R. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190173 · Cited by 73
Cook, L. E., Locke, M. C., Young, A. R., Monte, K. J., Hedberg, M. L., Shimak, R. M. K., Sheehan, K. C. F., Novack, D. V., Diamond, M., & Lenschow, D. J. (2019) · Journal of Virology · doi:10.1128/jvi.00841-19 · Cited by 74
Early type I IFN blockade improves the efficacy of viral vaccines
Palacio, N. M., Dangi, T., Chung, Y. R., Wang, Y., Loredo-Varela, J.-L., Zhang, Z., & Penaloza‐MacMaster, P. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191220 · Cited by 72
Jin, M. L., & Jeong, K. W. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01014-z · Cited by 76
DDX6 Represses Aberrant Activation of Interferon-Stimulated Genes
Lumb, J. H., Li, Q., Popov, L. M., Ding, S., Keith, M. T., Merrill, B. D., Greenberg, H. B., Li, J. B., & Carette, J. E. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.06.085 · Cited by 75
“Perturbations of IFN expression or signaling contribute to the etiology of several autoimmune diseases, dysregulated antiviral responses, and cancer (Corrales et al., 2017; Crow and Manel, 2015; Davidson et al., 2014; Pylaeva et al., 2016; Wilson et al., 2013).”
BackgroundTRIM33 switches off Ifnb1 gene transcription during the late phase of macrophage activation
Ferri, F., Parcelier, A., Petit, V., Gallouet, A.-S., Lewandowski, D., Dalloz, M., van den Heuvel, A., Kolovos, P., Soler, E., Squadrito, M. L., et al. (2015) · Nature Communications · doi:10.1038/ncomms9900 · Cited by 70
Madelain, V., Baize, S., Jacquot, F., Reynard, S., Fizet, A., Barron, S., Solas, C., Lacarelle, B., Carbonnelle, C., Mentré, F., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06215-z · Cited by 70
Jin, J., Mu, Y., Zhang, H., Sturmlechner, I., Wang, C., Jadhav, R. R., Xia, Q., Weyand, C. M., & Goronzy, J. J. (2023) · Nature Aging · doi:10.1038/s43587-023-00399-w · Cited by 77
Cook, K. D., Kline, H. C., & Whitmire, J. K. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.4hi1214-594r · Cited by 79
“A set of papers recently identified an inhibitory role for type I IFN in limiting antiviral T cell responses during the chronic stage of LCMV infection [9, 10].”
BackgroundType I interferon is a therapeutic target for virus-induced lethal vascular damage
Baccalà, R., Welch, M. J., González‐Quintial, R., Walsh, K. B., Teijaro, J. R., Nguyen, A., Ng, C. T., Sullivan, B. M., Zarpellon, A., Ruggeri, Z. M., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408148111 · Cited by 70
“Although IFN-I has long been thought to protect the host from viral infections due to potent antiviral and immune response-promoting effects, recent studies have implicated these cytokines in harming the host in a number of viral and bacterial infections (24, 25, 39, 40).”
BackgroundMourik, B. C., Lubberts, E., de Steenwinkel, J. E. M., Ottenhoff, T. H. M., & Leenen, P. J. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00294 · Cited by 76
“gests divergent effector functions (328, 329).”
T‐cell exhaustion in CAR‐T ‐cell therapy and strategies to overcome it
Yin, X., He, L., & Guo, Z. (2023) · Immunology · doi:10.1111/imm.13642 · Cited by 74
“Although type I IFNs such as IFN-α and IFN-β have antiviral functions in infection and thus promote the differentiation and activation of CD8+ T cells [36], blocking the IFN-α/β pathway reverses or prevents T-cell exhaustion during LCMV clone 13 infection [37].”
BackgroundRausch, L., & Kallies, A. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082223-044122 · Cited by 70
Manipulating IL-10 signalling blockade for better immunotherapy
Ni, G., Wang, T., Walton, S. F., Zhu, B., Chen, S., Wu, X., Wang, Y., Wei, M. Q., & Liu, X. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2014.12.012 · Cited by 71
“that blockade of type 1 interferon signalling by using an IFN-I receptor neutralizing antibody resulting enhanced virus clearance [51,52].”
MethodTwenty-five years of type I interferon-based treatment: A critical analysis of its therapeutic use
Antonelli, G., Scagnolari, C., Moschella, F., & Proietti, E. (2014) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.12.006 · Cited by 73
“For instance the detrimental effects of type I IFN action are clearly demonstrable during lymphocytic choriomeningitis virus (LCMV), pathogenic simian immunodeficiency virus (SIV) and HIV infections where a direct causal link between type I IFN/ISGs expression and chronic immune activation and dysfunction has been rep…”
Odorizzi, P. M., & Wherry, E. J. (2013) · Science · doi:10.1126/science.1237568 · Cited by 68
Metadata
- Authors
- Wilson, E. B., Yamada, D. H., Elsaesser, H., Herskovitz, J., Deng, J., Cheng, G., Aronow, B. J., Karp, C. L., & Brooks, D. G.
- Affiliations
- University of California, Los Angeles (US)
- Cincinnati Children's Hospital Medical Center (US)
- Corresponding author
- Brooks, David G.
- ORCID
- Venue
- Science
- Published
- 2013-04-12
- Volume
- 340
- Issue
- 6129
- Pages
- 202-207
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3704950
- OpenAlex
- W2049868800
- Cited by
- 709
- References
- 29
- Citations by year
- 2026: 26 · 2025: 37 · 2024: 34 · 2023: 35 · 2022: 35 · 2021: 48 · 2020: 50 · 2019: 50 · 2018: 58 · 2017: 72 · 2016: 87 · 2015: 72 · 2014: 70 · 2013: 34
- FWCI
- 48.52
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000077)
- National Heart, Lung, and Blood Institute (R01HL108949, HL108949)
- National Institute of Allergy and Infectious Diseases (AI060567, T32AI060567, U01AI082975, R01AI085043, AI082975, R01AI056154, AI085043, R01AI047868, P30AI028697)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (P50AR063020)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- type I interferon signaling, chronic infection, lymphocytic choriomeningitis virus, viral persistence, immune activation, immunosuppression, CD4+ T cells, interferon-gamma, antiviral immunity, viral clearance
- MeSH terms
- Animals, Antibodies, Arenaviridae Infections, Dendritic Cells, Immune Tolerance, Interferon Type I, Interferon-gamma, Lymphocytic choriomeningitis virus, Virus Replication, Signal Transduction, CD4-Positive T-Lymphocytes, Cytokines, Interleukin-10, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Mice, Receptor, Interferon alpha-beta, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.